Macrogenics (MGNX) EBT Margin (2012 - 2026)
Macrogenics (MGNX) posted quarterly EBT Margin of 187.28% for Q1 2026, up 13651.0% year-over-year from N/an in Q1 2025, and down 417.08% quarter-over-quarter from 36.22% in Q4 2025.
Macrogenics (MGNX) EBT Margin (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has reported EBT Margin for 15 consecutive years, with 187.28% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT Margin rose 13651.0% year-over-year to 187.28%; the TTM figure through Mar 2026 stood at 46.58% (down 1421.0% YoY), while the FY2025 annual figure was 50.36%, down 634.0% from the prior year.
- EBT Margin declined to 187.28% in Q1 2026 per MGNX's latest filing, from 36.22% in the prior quarter.
- Across five years, EBT Margin topped out at 50.86% in Q3 2024 and bottomed at 1100.56% in Q1 2024.
- Historically, EBT Margin has averaged 261.74% across 5 years, with a median of 187.28% in 2026.
- Annual changes were most pronounced in 2022 — EBT Margin soared 274367 bps — and 2024, when it slumped 91174 bps.
- Macrogenics' EBT Margin stood at 16.39% in 2022, then slumped by 2908 bps to 460.39% in 2023, then surged by 92 bps to 36.19% in 2024, then declined by 0 bps to 36.22% in 2025, then plunged by 417 bps to 187.28% in 2026.
- Business Quant data shows MGNX's EBT Margin at 187.28% in Q1 2026, 36.22% in Q4 2025, and 23.09% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | Macrogenics | 268.22 Mn | 201.71 Mn | - | -187.28% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -187.28% |
| Dec 31, 2025 | -36.22% |
| Sep 30, 2025 | 23.09% |
| Jun 30, 2025 | -162.52% |
| Mar 31, 2025 | -323.79% |
| Dec 31, 2024 | -36.19% |
| Sep 30, 2024 | 50.86% |
| Jun 30, 2024 | -515.55% |
| Mar 31, 2024 | -1,100.56% |
| Dec 31, 2023 | -460.39% |
| Sep 30, 2023 | -341.46% |
| Jun 30, 2023 | -358.21% |
| Mar 31, 2023 | -188.82% |
| Dec 31, 2022 | 16.39% |
| Sep 30, 2022 | -59.80% |
| Jun 30, 2022 | -160.76% |
| Mar 31, 2022 | -608.43% |
| Dec 31, 2021 | -2,727.28% |
| Sep 30, 2021 | -465.53% |
| Jun 30, 2021 | -306.29% |